Goodman Advisory Group LLC Has $6.31 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Goodman Advisory Group LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,915 shares of the biopharmaceutical company's stock after selling 17,821 shares during the period. Gilead Sciences makes up 2.1% of Goodman Advisory Group LLC's holdings, making the stock its 13th largest position. Goodman Advisory Group LLC's holdings in Gilead Sciences were worth $6,312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences in the 4th quarter worth $208,000. Tyche Wealth Partners LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth $420,000. HealthInvest Partners AB acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $8,018,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Gilead Sciences by 5.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,491,253 shares of the biopharmaceutical company's stock worth $120,806,000 after purchasing an additional 73,824 shares during the period. Finally, Wealth Alliance raised its position in shares of Gilead Sciences by 3.5% during the fourth quarter. Wealth Alliance now owns 11,687 shares of the biopharmaceutical company's stock worth $947,000 after purchasing an additional 396 shares during the period. Institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company's stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.29% of the company's stock.

Gilead Sciences Stock Down 0.6 %

NASDAQ GILD traded down $0.38 on Wednesday, reaching $66.93. The stock had a trading volume of 5,283,342 shares, compared to its average volume of 7,319,696. The business has a 50 day moving average price of $72.25 and a 200 day moving average price of $76.66. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 1 year low of $66.89 and a 1 year high of $87.86. The company has a market capitalization of $83.33 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 0.86 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts' consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same period in the prior year, the firm earned $1.67 EPS. Gilead Sciences's quarterly revenue was down 3.7% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a $0.77 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.60%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.75. Gilead Sciences's payout ratio is currently 68.44%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GILD. Cantor Fitzgerald cut their target price on Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 7th. Truist Financial downgraded Gilead Sciences from a "buy" rating to a "hold" rating and lowered their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, February 22nd. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 14th. Finally, StockNews.com upgraded Gilead Sciences from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $85.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.